Metabolic & Cardiometabolic

ezetimibe decreases LDL cholesterol (~18-20%)

In plain terms: Does ezetimibe meaningfully lower LDL cholesterol?

Strong support Metabolic & Cardiometabolic 🔬 Includes disconfirming

RefutedContestedStrong support

consensus score 0.81

Yes — ezetimibe lowers LDL by roughly 15-20% as monotherapy and adds a similar increment on top of a statin, a modest but reliable and well-documented effect.

📅 Last reviewed: 2026-07-15 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

14 support 0 contradict 1 tested null 1 mixed · 16 sources, 13 independent groups

What the evidence shows

Ezetimibe reliably lowers LDL cholesterol, by roughly 15 to 20 percent as monotherapy and a similar increment added on top of a statin. IMPROVE-IT, in 18,144 patients after acute coronary syndrome, cut LDL a further 24 percent and reduced cardiovascular events, so the lipid effect translates into outcomes. Modest next to a statin, but well documented and consistent.

Cochrane agrees with us see how our grade compares ▾

Cochrane review 2018 · moderate to high (CV endpoints) Agrees with our grade

LDL lowering is described as the likely mechanism rather than being the review's primary endpoint.

“Same Cochrane ezetimibe review (CD012502.pub2): 'The cardiovascular benefit of ezetimibe might involve the reduction of LDL-C, total cholesterol and triglycerides.'”

Why we agree: we reached the same direction independently, from our own appraisal of 16 sources. Two methods landing in the same place is a stronger signal than either alone.

What is Cochrane, and why trust it?

Cochrane produces systematic reviews: instead of running a new study, they gather every trial ever done on a question, judge how well each was run, and pool the results. They take no commercial or industry funding, which is why the medical community treats their reviews as a gold standard — and why we check our own verdicts against theirs.

About Cochrane ↗ · Get involved / support ↗

Read the Cochrane review ↗

The evidence (18)

Source	Grade	Stance	Quality	Finding
White RT, Ansong BO, Cowart K 2026 · Journal of clinical lipidology	observational	supports	moderate	Retrospective cohort (TriNetX, n=6706) comparing bempedoic acid vs ezetimibe added to moderate-intensity statins found LDL-C reduction was greater with ezetimibe than with bempedoic acid (no numeric ezetimibe-only % given), despite bempedoi
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, IMPROVE-IT Investigators 2015 · N Engl J Med	RCT	supports	high	IMPROVE-IT: ezetimibe added to simvastatin in 18,144 post-ACS patients lowered LDL ~24% more (69→54 mg/dL) and cut CV events — outcomes proof it matters.
Inia JA, Zhang LH, Keijzer N, Worms N, van Nieuwkoop-van Straalen A, Ditmarsch M, de Kleer M, Jukema JW, Kastelein JJP, Szarek M, van den Hoek AM, Stokman G, Pieterman EJ, Princen HMG 2026 · Journal of lipid research	animal	supports	moderate	APOE3-Leiden.CETP mice on a Western diet: ezetimibe monotherapy reduced non-HDL-C by 19%, and ezetimibe+obicetrapib combination reduced it by 75%, versus controls.
Tellier P 2003 · Ann Endocrinol (Paris)	meta-analysis	supports	moderate	Narrative review (Tellier 2003, French) re-reporting phase III results, no own synthesis described: 'As monotherapy, mean decrease in LDL-C with ezetimibe was 19.1% versus placebo, whereas in addition to ongoing statin therapy, there was a 21.8% incremental reduction of LDL-C (p<0.001)'. The underlying trials/pooled analyses are counted elsewhere - zero weight.
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R, SHARP Investigators 2011 · Lancet	RCT	mixed	high	SHARP: simvastatin+ezetimibe in 9,270 CKD patients lowered LDL ~0.85 mmol/L and cut major atherosclerotic events 17% — combination benefit.
Khan SU, Rahman H, Okunrintemi V, Riaz H, Khan MS, Sattur S, Kaluski E, Lincoff AM, Martin SS, Blaha MJ 2019 · J Am Heart Assoc	meta-analysis	tested-null	high	Network meta-analysis of lipid therapies: ezetimibe add-on gave a consistent extra LDL reduction that tracked with proportional CV risk reduction per mmol/L.
Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, Shah AK, Tershakovec AM 2012 · Atherosclerosis	meta-analysis	supports	high	Pooled analysis of 27 trials (>21,000 patients): ezetimibe added to statin lowered LDL ~15-20% more than statin alone across statin types and doses.
Catapano AL, Mikhailova E, Navar AM, Banka P, Corral P, Saxena M, Steg PG, Verma S, Kordahi AY, Mendizabal G, Zhu P, Ballantyne CM, CORALreef AddOn Investigators 2026 · Journal of the American College of Cardiology	RCT	supports	high	Phase 3 RCT (n=301) in statin-treated adults: ezetimibe 10mg monotherapy arm (n=50) produced a -27.8% (95% CI -32.3 to -23.4%) mean change in LDL-C from baseline over 56 days, versus -64.6% with enlicitide.
He H, Tang J, Yan VKC, Blais JE, Wong CK, Tam MTK, Yiu HHE, Tse HF, Chan EWY 2026 · The Lancet regional health. Western Pacific	observational	supports	moderate	Propensity-matched cohort (1,452 vs 5,808) found statin+ezetimibe combination therapy produced a greater LDL-C reduction than high-intensity statin monotherapy (relative difference -10.6%, 95% CI -14.1 to -7.2%).
Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP, Ezetimbe Study Group 2003 · Int J Clin Pract	RCT	supports	high	Pooled phase III monotherapy analysis: ezetimibe 10mg lowered LDL ~18% vs placebo in primary hypercholesterolemia — the pivotal monotherapy magnitude.
Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, Reist C, McCagg A, Braunwald E, Califf RM 2014 · Am Heart J	RCT	supports	high	In 18,144 post-ACS patients, adding ezetimibe to simvastatin further lowered LDL-C and modestly reduced cardiovascular events versus statin alone.
Yasmin F, Moeed A, Umar M, Zaidi F, Khan MS, Alraies MC 2025 · J Lipid Atheroscler	meta-analysis	supports	moderate	Meta-analysis of RCTs found moderate-intensity statin plus ezetimibe achieved LDL-C reduction comparable to high-intensity statin monotherapy.
Mikhailidis DP, Lawson RW, McCormick AL, Sibbring GC, Tershakovec AM, Davies GM, Tunceli K 2011 · Curr Med Res Opin	meta-analysis	supports	high	Meta-analysis: adding ezetimibe to a statin lowered LDL more than doubling/titrating the statin, confirming a consistent ~15-20% incremental effect.
Liu HH, Liu ZH, Chen SS, Zhu CG, Li JJ 2026 · American journal of cardiovascular drugs : drugs, devices, and other interventions	observational	supports	low	Narrative review states ezetimibe monotherapy reduces LDL-C by approximately 17.1-25.9%, with additional LDL-C reduction and improved goal attainment when added to statins.
Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP, Ezetimibe Study Group 2003 · Circulation	RCT	supports	high	In 628 patients, ezetimibe added to atorvastatin gave an incremental ~12-14% LDL reduction beyond statin alone, roughly equal to tripling the statin dose.
Lu YW, Fang CC, Cheng YT 2026 · Acta Cardiologica Sinica	observational	supports	low	Retrospective cohort of 120 post-PCI patients on pitavastatin+ezetimibe combination; LDL-C decreased 32.54% from baseline after 12 months.
Gagné C, Gaudet D, Bruckert E, Ezetimibe Study Group 2002 · Circulation	RCT	supports	moderate	Ezetimibe coadministered with statins lowered LDL a further ~21-25% versus statin plus placebo, including in difficult-to-treat familial hypercholesterolemia.
Abbas MS, Batool A, Hussain M, Hassan M, Sohaib A, Ahmed T, Athar M, Khan S, Kanwal W, Ali Akbar M, Hannan A 2026 · Future Cardiol	meta-analysis	supports	low	PROSPERO-registered (CRD420251233057) random-effects meta-analysis of RCTs of pitavastatin+ezetimibe 10 mg vs pitavastatin alone: 'The combination therapy significantly lowered “bad” cholesterol (LDL-C) more than pitavastatin alone, with approximately 13% more reduction at 12 weeks.' Quality low, not moderate: 'The researchers reviewed three clinical trials', all ≤12 weeks on a single statin with surrogate endpoints only, and the authors conclude 'the limited evidence warrants further research.' The published RESULTS section is a fragment with no effect sizes or CIs, so magnitude rests on the plain-language summary alone.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.